Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases

Gynecologic Oncology

Volumn 68, Issue 1, 1998, Pages 54-61

  Blom, René ^a   Guerrieri, Claudio ^a,b   Stål, Olle ^a   Malmström, Henric ^a   Simonsen, Ernst ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MITOSIS INDEX; ONCOGENE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; UTERUS MYOMA;

EID: 0031886985     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4889     Document Type: Article

References (32)

1. Nordal R, Kristensen G B, Kærn J, Stenwig A E, Pettersen E O, Tropé C. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine sarcoma. Acta Oncol. 34:1995;797-802.
2. Coppleson M, Monaghan J M, Morrow C P, Tattersall M HN. Gynecologic Oncology. 1992;Churchill Livingstone.
3. Bell S W, Kempson R L, Hendrickson M R. Problematic uterine smooth muscle neoplasms. Am J Surg Pathol. 18:1994;535-558.
4. El-Deiry W S, Tokino T, Velculesco V E. WAF1, a potential mediator of p53 suppression. Cell. 75:1993;817-825.
5. Lane D P. p53, guardian of the genome. Nature. 358:1992;15-16.
6. Levine A J, Pery M E, Chang A. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 69:1994;409-416.
7. Cordon-Cardo C, Latres E, Drobnjak M, Oliva M R, Pollack D, Woodruff J M, Marechal V, Chen J, Brennan M F, Levine J. Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:1994;794-799.
8. Chen J, Marechal V, Levine A. Mapping of the p53 and MDM2 interactions domains. Mol Cell Biol. 13:1993;4207-4114.
9. Merkel D E, Mcguire W L. Ploidy, proliferative activity and prognosis. Cancer. 65:1990;1194-1205.
10. Rosenberg P, Wingren S, Simonsen E, Stål O, Risberg B, Nordenskjöld B. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator. Gynecol Oncol. 35:1989;50-54.
11. Jakobsen A. Prognostic impact of ploidy level in carcinoma of cervix. Am J Clin Oncol. 7:1984;475-480.
12. Malmström H, Schmidt H, Persson P-G, Carstensen J, Nordenskjöld B, Simonsen E. Flow cytometry analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators. Gynecol Oncol. 44:1992;172-177.
13. Wolfson A, Wolfson D, Sittler S, Breton L, Markoe A, Schwade J, Houdek P, Averette H, Sevin B-U, Penalver M, Duncan R, Ganjei P. A multivariate analysis of clinopathologic factors for predecting outcome in uterine sarcomas. Gynecol Oncol. 52:1994;56-62.
14. Kjellberg L, Boquist L, Stendahl U, Tribukait B. Flow cytometry analysis of uterine sarcomas. Gynecol Oncol. 55:1994;339-342.
15. Peters W A III, Howard D R, Andersen W A, Figge D C. Deoxyribonucleic acid analysis by flow cytomery of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential. Am J Obstet Gynecol. 166:1992;1646-1653.
16. Tsushima K, Stanhope C R, Gaffey T A, Lieber M M. Uterine leiomyosarcomas and benign smooth muscle tumors: usefullness of nuclear DNA patterns studied by flow cytometry. Mayo Clin Proc. 63:1988;248-255.
17. Wingren S, Hatschek T, Stål O, Boeryd B, Nordenskjöld B. Comparison of static and flow cytofluorometry for estimation of DNA index and S-phase fraction in fresh and paraffin-embedded breast carcinoma tissue. Acta Oncol. 27:1988;793-797.
18. Vindelöv L L, Christensen I J, Nissen N I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 3:1983;323-327.
19. Hiddeman W, Schumann J, Andreeff M, Barlogie B, Herman C, Leif R, Mayall B H, Murphy R F, Sandberg A A. Convention on nomenclature for DNA cytometry. Cytometry. 5:1984;445-446.
20. Shankey T V, Rabinovitch P S, Bagwell B, Bauer K D, Duque R E, Hedley D W, Mayall B H, Wheeless L. Guidelines for implementation of clinical DNA cytometry. Cytometry. 14:1993;472-477.
21. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
22. Cox D R. Regression models and life-tables (with discussion). J R Statist Soc B. 34:1972;187-220.
23. Oláh K S, Gee H, Blunt S, Dunn J A, Kelly K, Chan K K. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer. 27:1991;1095-1099.
24. Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, Bazzurini L, Arisio R, Romagnolo C, Cristofani R. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 62:1996;25-32.
25. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol. 14:1995;134-142.
26. Liu F-S, Kohler M F, Marks J R, Bast R C, Boyd J, Berchuck A. Mutation and overexpression of the P53 tumor supressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol. 83:1994;118-124.
27. Niemann T H, Raab S S, Lenel J C, Rodgers J R, Robinson R A. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol. 26:1995;375-379.
28. O'Reilly P E, Raab S S, Nieman T H, Rodgers B S, Robinson R A. p53, proliferating cell nuclear antigen, and KI-67 expression in extrauterine leiomyosarcomas. Mod Pathol. 10:1997;91-97.
29. Patterson H, Gill S, Fisher C, Law M G, Jayatilaka H, Fletcher C D, Thomas M, Grimer R, Gusterson B A, Cooper C S. Abnormalities of the p53, MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer. 69:1994;1052-1058.
30. Nilbert M, Rydholm A, Willén H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosome in soft tissue tumors. Genes Chromosomes Cancer. 9:1994;261-265.
31. Florenes V A, Maelandsmo G M, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 86:1994;1297-1302.
32. Leach F S, Tokino T, Meltzer P, Burrell M, Oliner J D, Smith S, Hill D, Sidransky D, Kinzler K W, Vogelstein B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:1993;2231-2234.